United States - Remote, Belgium - Remote, Switzerland - Remote Remote (Global) $296,000.00 - $407,000.00 USD

Argenx is hiring a Clinical Development Indication Lead - Rheumatology

Requirements

  • Medical Doctor with rheumatology specialty education preferred ( other areas such as neurology, dermatology, immunology, internal medicine, pediatric are also of interest)
  • At least 3-5 years in the pharma/biotech industry, having acquired an in-depth understanding of end to end ( phase I to registration) drug development
  • Excellent English, both written and spoken is a must, as well as ability to travel
  • Proven leadership, motivational and interpersonal skills in a global and intercultural environment, including leading through influence
  • Pro-active problem solver with negotiation skills
  • Must provide clear vision, direction, and purpose to the different study teams
  • Demonstrated expertise in clinical trial design, conduct and interpretation of clinical data
  • Strong communication skills to ensure that study plans and status are transparent, and that risks, issues, and results are clear to all involved parties
  • Additional skills in gathering decision information, negotiation and communicating decisions and action
  • Executes responsibilities with knowledge, accuracy, persistence, resilience and creativity, being an accomplished team player whilst maintaining medical integrity

Nice to Have

  • Rheumatology specialty education

Work Arrangement

Remote (Worldwide)

Team

Structure: Cross-functional team including Global Clinical Trial Physicians and functional groups; part of the clinical development team for a specific indication

Additional Information

  • Ability to travel
  • Excellent English, both written and spoken
About company
Argenx
Argenx is a biotech company transforming immunology and delivering medicines that help autoimmune patients get their lives back. The company is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, a first-in-class neonatal Fc receptor blocker approved for the treatment of gMG.
All jobs at Argenx Visit website
Job Details
Category other
Posted 3 months ago